Eton PharmaceuticalsETON
Recorded

Eton Pharmaceuticals 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration44 minParticipants9

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good day, and thank you for standing by. Welcome to the Eton Pharmaceuticals Third Quarter 2026 Earnings Conference Call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I will now hand the conference over to your first speaker today, David Krempa, Chief Business Officer at Eton Pharmaceuticals.

David KrempaChief Business Officer

Please go ahead. Thank you, operator.

David KrempaChief Business Officer

Good afternoon, everyone, and welcome to Eton's Third Quarter 2026 Conference Call. This afternoon, we issued our earnings release, which is available on our website, etonpharma.com. Joining me today are Sean Brynjelsen, our CEO, Ipek Trinkaus, our Chief Commercial Officer, and Judy Matthews, our Chief Financial Officer. Before we begin, I would like to remind everyone that remarks made during the call may contain forward-looking statements and involve risks and uncertainties that could cause actual results to differ materially from those contained in these forward-looking statements. Please see the forward-looking statements disclaimer in our earnings release and the risk factors in the company's filings with the SEC. Now, I will turn the call over to our CEO, Sean Brynjelsen.

Sean BrynjelsenCEO

Thank you, David. Good afternoon, everyone, and thank you for joining us today. It was another outstanding quarter for Eton, with record revenue, significant margin expansion, and strong cash flow generation. We continue to fire on all cylinders on both the commercial and development fronts. Revenue grew a remarkable 158% year-over-year, reaching $57.9 million in the quarter. The third quarter was the first with a full quarter of HEMANGEOL revenue, which was a significant growth driver, but we also saw strength across all our key products. In fact, we hit record high levels of active patient counts in the quarter on all of our key branded products, including INCRELEX, HEMANGEOL, ALKINDI SPRINKLE, KHINDIVI, GALZIN, and DESMODA. At the start of 2026, we set three ambitious long-term goals for the company to help articulate to investors where we saw our business heading in the coming years.

Sean BrynjelsenCEO

We like to set aspirational goals that push the envelope, not easy goals, and I know there was initially some skepticism about how achievable our goals were. From today's results, it is clear we are well ahead of that schedule. Our first goal was to reach a $200 million annualized revenue run rate by the end of 2027. We exited 2025 at about an $85 million run rate, so this required us to more than double our revenue within 24 months. As you saw, with nearly $58 million of revenue this quarter, we far exceeded this goal and did so an impressive five quarters ahead of schedule. Our second goal was focused on profitability, to produce a 50% Adjusted EBITDA margin by 2028, up from the 20% we reported in 2025. It happened much faster. This quarter, we achieved a 49% Adjusted EBITDA margin, even after the expensing of our $3 million licensing payment for ASN-001, which was not adjusted out of the calculation.

Sean BrynjelsenCEO

Our Adjusted EBITDA margin may fluctuate quarter to quarter depending on the timing and size of certain R&D investments, but we believe we will now be operating in the ballpark of a 50% EBITDA margin over the coming quarters, and it should continue to increase in future years if revenue grows at the rate we expect it to. Our third goal was to reach $500 million of revenue in 2030. Once again, we believe we are well ahead of the pace we originally envisioned.

Sean BrynjelsenCEO

Based on the Q3 run rate, we are nearly halfway to $500 million, and the recent additions of ASN-001, HEMANGEOL, and now LIBERVANT have significantly increased our future revenue expectations compared to the levels that were expected at the start of 2026. Speaking of LIBERVANT, we are very excited about the transaction we announced just a few weeks ago to license the product. LIBERVANT is an orphan drug-designated differentiated treatment for seizure clusters in patients with epilepsy awaiting FDA approval. LIBERVANT's innovative buccal film formulation offers an alternative to existing nasal and rectal seizure rescue treatments, a market that currently exceeds $450 million annually in the U.S. Portability matters in this rescue therapy market. In the exploratory patient market research, roughly three-quarters of those surveyed were concerned about how their rescue medication within reach went away from home, yet only about one-third said they always carried it.

Sean BrynjelsenCEO

That's a need we see an opportunity to address with LIBERVANT's portable film format once it is approved by the FDA. LIBERVANT is currently tentatively approved for patients with epilepsy ages two to five and ages 12 and older. An NDA under review would add ages six to 11 to the label and has a late March PDUFA date. Subject to final FDA approval and resolution of applicable exclusivity restrictions, we anticipate launching in April 2027, and launch preparations are underway. LIBERVANT's film formulation builds on our experience commercializing differentiated dosage forms, including pediatric liquid and granules. The prescriber base also fits our commercial model. Nearly half of the market is concentrated among pediatric neurologists, a relatively small specialist base that we believe we can effectively reach with Eton's targeted sales force strategy. LIBERVANT offers a near-term growth driver and an entry into pediatric neurology.

Sean BrynjelsenCEO

We believe pediatric neurology is one of the most attractive specialties that we are not already in. There are numerous orphan products approved and under development within neurology, including our recently announced ET-900 program, which I will discuss shortly. So we believe there is a compelling opportunity for us to build up an attractive presence in the space, similar to what we have successfully done in pediatric endocrinology. Q3 was, without a doubt, the best commercial quarter in our history, but the developments in our pipeline over the last few months are even more exciting than our blockbuster financial results. I believe what is brewing in our pipeline will make our current levels look inconsequential within a few years.

Sean BrynjelsenCEO

Our pipeline has been transformed in the last few months with the addition of two extremely high-value programs, as well as the achievement of critical development milestones that have advanced our programs closer to commercialization. I think it is worth dedicating more time to our pipeline this quarter. Our pipeline now has nine programs, three of which could launch in 2027, and four that we believe have greater than $100 million revenue potential. I will start with our newest addition, ET-900, which was just announced this week. Infantile spasms are a devastating condition that causes frequent seizures in very young children and can be associated with lasting development impairment. Unfortunately, around half of the patients do not respond to current treatment options, underscoring the need for new therapies. Dr. Swann's research at Baylor showed that the active ingredient in INCRELEX was highly effective at treating spasms in animal models.

Sean BrynjelsenCEO

We have spent nearly a year preparing for this development and have now licensed patents from Baylor College of Medicine covering this indication. An investigator-initiated phase II study has been planned, with enrollment anticipated to begin in the first quarter of 2027. Because changes in spasm frequency may be observed within weeks of starting therapy, preliminary clinical data could be available as early as mid-2027. While this is an earlier stage opportunity than Eton traditionally pursues, it offers a substantial opportunity to leverage one of our existing assets to potentially address a serious unmet need. We believe for a total investment of less than $1 million, we can get through a proof-of-concept phase II study, which will have the potential to verify efficacy for an incredibly important new treatment option. An estimated 2,500 patients each year are diagnosed with infantile spasms annually in the U.S.

Sean BrynjelsenCEO

If successful and approved, we believe the product could generate annual revenue in the hundreds of millions of dollars. Today, we also released exciting results from our proof-of-concept study for ET-700, our extended-release zinc product. The three-arm proof-of-concept study compared ET-700 to GALZIN and to placebo. We believe the results validated our thesis that an extended-release zinc formulation could reduce GI discomfort and adverse events. Lowering adverse events could drastically improve adherence and drive superior outcomes for patients. Treatment-related adverse events occurred in only one of 12 ET-700 participants, compared with eight of 12 GALZIN participants. ET-700 blocked copper absorption better than placebo, but not as well as our existing GALZIN product. We believe our release profile is actually too slow to maximize efficacy, and we have a strong plan to address it. We initially used a slower release profile.

Sean BrynjelsenCEO

It may not have fully released by the time the product moved out of the small intestine, where the metallothionein is produced. During formulation development, we had worked on a number of different formulations with varying release profiles, so we already have additional faster-release formulations identified that we think could deliver what we are looking for. We will be running additional arms as part of the same clinical study protocol, which will allow us to quickly test the formulations with faster release profiles. We expect to run the follow-up arms in 2027, and we believe these faster release profiles will allow us to improve efficacy while preserving the attractive safety profile. During the third quarter, we closed the licensing of ASN-001. I discussed the program briefly on our last call.

Sean BrynjelsenCEO

Just days after our licensing transaction, but after an additional three months of conversations with the physician community, including an advisory board at the recent Pediatric Dermatology Research Alliance annual meeting, we feel even more confident that ASN-001 will address a significant unmet need and is poised to become the largest revenue-generating product in our portfolio. While there are estimated to be more than 100,000 infants born in the U.S. every year with hemangiomas, only the most severe 10%, or roughly 10,000-15,000 infants, are candidates for systemic therapy with HEMANGEOL. HEMANGEOL is an FDA-approved treatment with a well-established safety and efficacy profile and remains an important treatment option for infants who require systemic therapy. However, physicians, especially general pediatricians and dermatologists, are selective about prescribing systemic therapy for infants, particularly for less severe cases.

Sean BrynjelsenCEO

Some parents can also be hesitant to give their babies a systemic medication, especially when the condition is not considered severe enough to warrant that level of treatment. This creates a significant opportunity for an effective FDA-approved topical treatment that could appeal to both physicians and families of patients with moderate hemangiomas, which is believed to be many multiples of the HEMANGEOL candidates. In addition, as a new product launch, ASN-001 will have much more favorable Medicaid rebate dynamics, which should translate to significantly higher net realized revenue per treatment compared to what we currently receive for HEMANGEOL. HEMANGEOL is a tremendous product that has been a home run success for the company, and we remain very enthusiastic about its continued growth.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day